Highlights
– GAME CHANGER randomized 504 adults with hospital‑acquired or healthcare‑associated Gram‑negative bloodstream infection to cefiderocol versus clinician‑chosen standard therapy and showed non‑inferiority for 14‑day all‑cause mortality (absolute risk difference 1%, 95% CI −3 to 6).
– In the predefined carbapenem‑resistant (CR) subset (25% of participants), mortality at 14 days was 14% with cefiderocol versus 10% with standard therapy (difference 5%, 95% CI −7 to 16); the trial was underpowered to demonstrate superiority in this subgroup.
